港股異動丨四環醫藥升6% 旗下胰島素注射液獲國家藥監局批准上市
四環醫藥(0460.HK)現升6%報0.53港元,最新市值49.4億港元。四環醫藥近日宣佈,集團旗下非全資附屬公司惠升生物製藥股份有限公司研發的德谷門冬雙胰島素注射液(商品名:惠優加®)已獲中國國家藥監局批准上市,用於治療成人2型糖尿病。是繼原研諾和諾德後國產首個獲批上市的德谷門冬雙胰島素注射液生物類似藥。糖尿病領域為惠升生物重點佈局領域,本次德谷門冬雙胰島素注射液獲國家藥監局批准上市,將能夠為廣大醫生患者提供更優化的控糖藥物,惠及更多中國患者,同時,也為集團及惠升生物的糖尿病藥物管線再添一重磅品種,該產品未來上市後將為集團和惠升生物的業績和增長帶來巨大新動能。此外,集團近日與韓國Cellontech Co., Ltd.就使用膠原蛋白的關節腔內注射劑產品CartiZol達成獨家代理協議,獲得該產品在中國大陸的獨家代理權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.